Dirnhofer S - Search Results

1

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA. Heinrich MC, et al. Among authors: dirnhofer s. J Clin Oncol. 2006 Mar 1;24(7):1195-203. doi: 10.1200/JCO.2005.04.0717. J Clin Oncol. 2006. PMID: 16505440

2

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.

Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG; Imatinib Target Exploration Consortium Study B2225. Heinrich MC, et al. Among authors: dirnhofer s. Clin Cancer Res. 2008 May 1;14(9):2717-25. doi: 10.1158/1078-0432.CCR-07-4575. Clin Cancer Res. 2008. PMID: 18451237 Clinical Trial.

3

Prevalence of KIT expression in human tumors.

Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, Sauter G. Went PT, et al. Among authors: dirnhofer s. J Clin Oncol. 2004 Nov 15;22(22):4514-22. doi: 10.1200/JCO.2004.10.125. J Clin Oncol. 2004. PMID: 15542802

4

Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment.

Lugli A, Went P, Khanlari B, Nikolova Z, Dirnhofer S. Lugli A, et al. Among authors: dirnhofer s. Virchows Arch. 2004 Mar;444(3):264-8. doi: 10.1007/s00428-003-0934-8. Epub 2003 Dec 16. Virchows Arch. 2004. PMID: 14677065

5

Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).

Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, Mey U, Pless M, Bargetzi M, Krasniqi F, Gigli F, Hany T, Samarin A, Biaggi C, Rusterholz C, Dirnhofer S, Zucca E, Martinelli G. Mamot C, et al. Among authors: dirnhofer s. J Clin Oncol. 2015 Aug 10;33(23):2523-9. doi: 10.1200/JCO.2014.58.9846. Epub 2015 Jul 6. J Clin Oncol. 2015. PMID: 26150440

6

Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.

Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, Dirnhofer S, Dettmer MS, Simillion C, Kaufmann BA, Chiu S, Keller M, Kleppe M, Hilpert M, Buser AS, Passweg JR, Radimerski T, Skoda RC, Levine RL, Meyer SC. Stivala S, et al. Among authors: dirnhofer s. J Clin Invest. 2019 Mar 4;129(4):1596-1611. doi: 10.1172/JCI98785. eCollection 2019 Mar 4. J Clin Invest. 2019. PMID: 30730307 Free PMC article.

7

V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.

Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A, Bihl MP. Agaimy A, et al. Among authors: dirnhofer s. J Clin Pathol. 2009 Jul;62(7):613-6. doi: 10.1136/jcp.2009.064550. J Clin Pathol. 2009. PMID: 19561230

8

Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia.

Lugli A, Ebnoether M, Cogliatti SB, Gratwohl A, Passweg J, Hess U, Korte W, Hawle H, Tinguely M, Borisch B, Mach-Pascual S, Von Juergensonn S, Tichelli A, Dirnhofer S. Lugli A, et al. Among authors: dirnhofer s. Hum Pathol. 2005 Jan;36(1):91-100. doi: 10.1016/j.humpath.2004.10.012. Hum Pathol. 2005. PMID: 15712187

9

Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays.

Pache M, Glatz K, Bösch D, Dirnhofer S, Mirlacher M, Simon R, Schraml P, Rufle A, Flammer J, Sauter G, Meyer P. Pache M, et al. Among authors: dirnhofer s. Virchows Arch. 2003 Dec;443(6):741-4. doi: 10.1007/s00428-003-0883-2. Epub 2003 Sep 26. Virchows Arch. 2003. PMID: 14513377

10

Frequent EpCam protein expression in human carcinomas.

Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S. Went PT, et al. Among authors: dirnhofer s. Hum Pathol. 2004 Jan;35(1):122-8. doi: 10.1016/j.humpath.2003.08.026. Hum Pathol. 2004. PMID: 14745734

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

363 results

Search Page

Filters